Clinical Trials Sponsored by Threshold Pharmaceuticals

Total 19492 results

Threshold Pharmaceuticals

Completed

Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias

Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | High-risk Myelodysplastic Syndrome | Advanced Myelofibrosis

United States
Threshold Pharmaceuticals

Unknown

Dose-Escalation Study of TH-302 in Combination With Sunitinib to Treat Patients With Advanced Renal Cell Carcinoma,Gastrointestinal Stromal Tumors and Pancreatic Neuroendocrine Tumors (TH-CR-410)

Gastrointestinal Stromal Tumors | Advanced Renal Cell Carcinoma | Pancreatic Neuroendocrine Tumors

United States
Threshold Pharmaceuticals

Terminated

Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer

Pancreatic Cancer

United States
Threshold Pharmaceuticals

Completed

Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors

Pancreatic Cancer | Non-Small Cell Lung Cancer | Prostate Cancer

United States
Threshold Pharmaceuticals

Terminated

Safety and Efficacy Study of Glufosfamide in Patients With Recurrent Sensitive Small Cell Lung Carcinoma

Carcinoma, Small Cell Lung

United States
Threshold Pharmaceuticals

Completed

Dose Escalation Trial of 2-Deoxy-D-Glucose (2DG) in Subjects With Advanced Solid Tumors

Breast Cancer | Head and Neck Cancer | Gastric Cancer | Pancreatic Cancer | Lung Cancer

United States
Threshold Pharmaceuticals

Terminated

Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia

Benign Prostatic Hyperplasia

United States
Threshold Pharmaceuticals

Terminated

A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma

Metastatic Melanoma

United States, Canada
Threshold Pharmaceuticals

Completed

Clinical Trial Testing TH-302 in Combination With Gemcitabine in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma (MAESTRO)

Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma

United States, Germany
Threshold Pharmaceuticals

Completed

Dose-Escalation Study of TH-302 in Combination With Doxorubicin to Treat Patients With Advanced Soft Tissue Sarcoma

Soft Tissue Sarcoma

United States
Threshold Pharmaceuticals

Unknown

A Cardiac Safety Study of TH-302 in Patients With Advanced Solid Tumors

Solid Tumors

United States
Threshold Pharmaceuticals

Unknown

Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

United States
Threshold Pharmaceuticals

Completed

A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors

Hypoxia | Tumors

United States
Threshold Pharmaceuticals
PPD

Completed

Study of the Efficacy and Safety of Glufosfamide Compared With Best Supportive Care in Metastatic Pancreatic Cancer

Pancreatic Cancer

United States, Brazil, Ukraine, India, Russian Federation, Romania, Hungary, Mexico, Argentina, Bulgaria, Czech Republic
Threshold Pharmaceuticals
PPD

Completed

Study of Safety and Efficacy of Glufosfamide in Combination With Gemcitabine in Cancer

Neoplasms | Pancreatic Neoplasms

United States, Brazil
Eleison Pharmaceuticals LLC.
Threshold Pharmaceuticals

Completed

Safety and Efficacy Study of Glufosfamide in Previously Treated Advanced Soft Tissue Sarcoma

Soft Tissue Sarcoma

United States
Threshold Pharmaceuticals
EMD Serono

Terminated

Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

United States, Germany, Spain, Poland, Greece, Czechia, Hungary, Italy, Romania, Russian Federation
Threshold Pharmaceuticals
PRA Health Sciences

Completed

Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma

Pancreatic Adenocarcinoma

United States
Threshold Pharmaceuticals
PRA Health Sciences

Terminated

Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia

Benign Prostatic Hyperplasia | Enlarged Prostate

Hungary, Poland, Germany, Italy
Threshold Pharmaceuticals
M.D. Anderson Cancer Center

Unknown

Immunotherapy Study of Evofosfamide in Combination With Ipilimumab

Melanoma | Pancreatic Cancer | Prostate Cancer | Squamous Cell Carcinoma of the Head and Neck

United States
Seoul National University Hospital
Threshold Pharmaceuticals

Completed

Study of TH-302 Monotherapy as Second-line Treatment in Advanced Biliary Tract Cancer

Biliary Tract Cancer

Korea, Republic of
Merck KGaA, Darmstadt, Germany
Threshold Pharmaceuticals

Completed

A Phase 1 TH-302 Mass Balance Trial

Solid Tumor

Germany
Merck KGaA, Darmstadt, Germany
Threshold Pharmaceuticals

Terminated

A Japanese Trial of TH-302 in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma

Soft Tissue Sarcoma

Japan
Merck KGaA, Darmstadt, Germany
Threshold Pharmaceuticals

Completed

A Japanese Phase 1 Trial of TH-302 in Subjects With Solid Tumors and Pancreatic Cancer

Pancreatic Cancer | Solid Tumor

Japan
Scripps Clinic Cancer Center
Threshold Pharmaceuticals

Unknown

TH-302 Plus Doxorubicin Delivered by Trans-Arterial Chemoembolization (TACE) in Patients With Hepatocellular Carcinoma

Hepatocellular Carcinoma

United States
Grupo Espanol de Tumores Neuroendocrinos
Pfizer; Threshold Pharmaceuticals

Completed

A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours

Pancreatic Neoplasms | Neuroendocrine Tumors

Spain
Maastricht Radiation Oncology
Threshold Pharmaceuticals; Zuyderland Medical Centre

Withdrawn

Testing TH-302, in Combination With Preoperative Chemoradiotherapy, in Esophageal Cancer.

Esophageal Cancer
Sarcoma Alliance for Research through Collaboration
Threshold Pharmaceuticals

No longer available

SARC021C: A Continuation Study of TH-CR-406/SARC021

Soft Tissue Sarcoma
Threshold Pharmaceuticals
Sarcoma Alliance for Research through Collaboration (SARC)

Completed

A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma

Soft Tissue Sarcoma

United States, France, Canada, Spain, Germany, Belgium, Poland, Austria, Denmark, Hungary, Israel, Italy, Russian Federation
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI); Threshold Pharmaceuticals

Completed

Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery

Kidney Cancer | Liver Cancer

United States
Herbert Hurwitz, MD
GlaxoSmithKline; National Comprehensive Cancer Network; Threshold Pharmaceuticals

Completed

Dose Escalation Study of Pazopanib Plus TH-302 (PATH)

Solid Tumors

United States
Novartis Pharmaceuticals
Chugai Pharmaceutical

Completed

Study of Safety and Efficacy of Letrozole Monotherapy as Second-line Endocrine Therapy in Postmenopausal Patients With Advanced Breast Cancer Who Received Previous Anti-estrogen Treatment

Postmenopausal Women With Advanced Breast Cancer

Japan
Novartis Pharmaceuticals
Chugai Pharmaceutical

Completed

Extension Study of 1.0mg Dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer

Postmenopausal Women With Advanced Breast Cancer

Japan
Novartis Pharmaceuticals
Chugai Pharmaceutical

Completed

Study of High-dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer

Postmenopausal Women With Advanced Breast Cancer

Japan
Illinois Institute of Technology
Arizona State University; Thresholds Inc.

Recruiting

Peer Navigators for the Health and Wellness of People With Psychiatric Disabilities (DRRRP-PHN)

Mental Disorder | Physical Illness

United States
Novartis Pharmaceuticals
Pharmaceutical Research Associates

Withdrawn

Pharmacokinetics Study of TNO155 in Participants With Mild, Moderate, or Severe Renal Impairment Compared to Matched Healthy Participants

Renal Impairment
Novartis Pharmaceuticals
Pharmaceutical Research Associates

Withdrawn

Pharmacokinetics of TNO155 in Participants With Mild, Moderate, or Severe Hepatic Impairment Compared to Matched Healthy Participants

Hepatic Impairment
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Completed

Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip (FACT OA2)

Osteoarthritis, Knee | Osteoarthritis, Hip

United States
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

A Study of EDP-514 in Patients With Chronic Hepatitis B Virus Infection Who Are Not Currently on Treatment

Chronic HBV Infection

Hong Kong, Taiwan
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Terminated

Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee (FACT CLBP 1)

Osteoarthritis | Chronic Low Back Pain

United States
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

Drug-Drug Interaction Study Between EDP-938, Itraconazole, Rifampin, and Quinidine in Healthy Subjects

RSV Infection

United States
Melior Pharmaceuticals
Bukwang Pharmaceutical, Co., Ltd.

Completed

Adult Subjects With Uncontrolled Type 2 Diabetes

Type 2 Diabetes

United States
Tibotec Pharmaceuticals, Ireland
Tibotec Pharmaceutical Limited

Completed

A Safety Study to Evaluate the Antiviral Activity of Darunavir in Combination With Ritonavir in HIV 1 Infected Children

Human Immunodeficiency Virus 1

South Africa, Argentina, Brazil, India, Kenya
Vertex Pharmaceuticals Incorporated
Tibotec Pharmaceutical Limited

Completed

A Study to Examine the Effects of Telaprevir on the Pharmacokinetics of Cyclosporine and Tacrolimus in Healthy Adults

Hepatitis C

United States
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Terminated

Study to Evaluate Arthroplasty Specimens for Osteoarthritis of the Knee and Hip

Osteoarthritis, Knee | Osteoarthritis, Hip

United States, Poland, United Kingdom
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

Drug-Drug Interaction Study Between EDP-938, Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in Healthy Subjects

RSV Infection

United States
Vertex Pharmaceuticals Incorporated
Tibotec Pharmaceutical Limited

Completed

A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response

Hepatitis C

Belgium, United States, Puerto Rico, Netherlands
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Completed

To Assess the Patients' Ability to Self-Administer Fasinumab (FACT DEVICE)

Osteoarthritis, Knee | Osteoarthritis, Hip

United States
Alexza Pharmaceuticals, Inc.
Pharmaceutical Research Associates

Unknown

Observational Study Evaluating the Safety of ADASUVE® in Agitation Associated With Schizophrenia or Bipolar I Disorder

Agitation,Psychomotor

United States
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

Drug-Drug Interaction Study Between EDP-938, Cyclosporine and Prednisone in Healthy Adult Subjects

RSV Infection

United States

Clinical Trials Sponsored by Threshold Pharmaceuticals

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kenya

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations